Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 43

1.

BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signalling.

Urban BC, Collard TJ, Eagle CJ, Southern SL, Greenhough A, Hamdollah-Zadeh M, Ghosh A, Poulsom R, Paraskeva C, Silver A, Williams AC.

Gut. 2015 Jun 1. pii: gutjnl-2014-308270. doi: 10.1136/gutjnl-2014-308270. [Epub ahead of print]

2.

Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.

Wang J, Carvajal-Carmona LG, Chu JH, Zauber AG; APC Trial Collaborators, Kubo M, Matsuda K, Dunlop M, Houlston RS, Sieber O, Lipton L, Gibbs P, Martin NG, Montgomery GW, Young J, Baird PN, Ratain MJ, Nakamura Y, Weiss ST, Tomlinson I, Bertagnolli MM.

Clin Cancer Res. 2013 Dec 1;19(23):6430-7. doi: 10.1158/1078-0432.CCR-13-0550. Epub 2013 Oct 1.

3.

Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial.

Arber N, Spicak J, Rácz I, Zavoral M, Breazna A, Gerletti P, Lechuga MJ, Collins N, Rosenstein RB, Eagle CJ, Levin B.

Am J Gastroenterol. 2011 Jun;106(6):1135-46. doi: 10.1038/ajg.2011.116. Epub 2011 Apr 19.

PMID:
21503000
4.

Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study.

Huang K, Gutierrez LP, Bülow S, Gallinger S, Castells A, Eagle CJ, Church JM.

Fam Cancer. 2011 Jun;10(2):303-8. doi: 10.1007/s10689-011-9423-4.

PMID:
21359561
5.

Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial.

Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG; Adenoma Prevention with Celecoxib (APC) Study Investigators.

Cancer Prev Res (Phila). 2010 May;3(5):588-96. doi: 10.1158/1940-6207.CAPR-09-0271. Epub 2010 Apr 19.

6.

Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET; Adenoma Prevention with Celecoxib Study Investigators.

Cancer Prev Res (Phila). 2009 Apr;2(4):310-21. doi: 10.1158/1940-6207.CAPR-08-0206. Epub 2009 Mar 31.

7.

Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.

Chan AT, Zauber AG, Hsu M, Breazna A, Hunter DJ, Rosenstein RB, Eagle CJ, Hawk ET, Bertagnolli MM.

Gastroenterology. 2009 Jun;136(7):2127-2136.e1. doi: 10.1053/j.gastro.2009.02.045. Epub 2009 Feb 21.

8.

Aberrant crypt foci in the adenoma prevention with celecoxib trial.

Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Wilton A, Sontag S, Nishioka N, Giardiello FM, Saltzman JR, Gostout C, Eagle CJ, Hawk ET, Bertagnolli MM.

Cancer Prev Res (Phila). 2008 Jun;1(1):21-31. doi: 10.1158/1940-6207.CAPR-07-0011. Epub 2008 Apr 14.

9.

Measuring the immeasurable? Assessing the quality of anaesthetic care.

Eagle CJ.

Curr Opin Anaesthesiol. 1998 Apr;11(2):203-7.

PMID:
17013221
10.

Celecoxib for the prevention of colorectal adenomatous polyps.

Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B; PreSAP Trial Investigators.

N Engl J Med. 2006 Aug 31;355(9):885-95.

11.

Celecoxib for the prevention of sporadic colorectal adenomas.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET; APC Study Investigators.

N Engl J Med. 2006 Aug 31;355(9):873-84.

12.

Developing a comprehensive patient safety strategy for an integrated Canadian healthcare region.

Flemons WW, Eagle CJ, Davis JC.

Healthc Q. 2005;8 Spec No:122-7. No abstract available.

13.

The characteristics of excellent clinical teachers.

Shysh AJ, Eagle CJ.

Can J Anaesth. 1997 Jun;44(6):577-81. English, French. No abstract available.

PMID:
9187774
14.

Somatosensory evoked potential monitoring during cardiac surgery: an examination of brachial plexus dysfunction.

Seal D, Balaton J, Coupland SG, Eagle CJ, MacAdams C, Kowalewski R, Bharadwaj B.

J Cardiothorac Vasc Anesth. 1997 Apr;11(2):187-91.

PMID:
9105991
15.

Anaesthetic management of a patient with myasthenia gravis and tracheal stenosis.

Froelich J, Eagle CJ.

Can J Anaesth. 1996 Jan;43(1):84-9.

PMID:
8665642
16.

Anaesthesia for coronary artery bypass surgery supplemented with subarachnoid bupivacaine and morphine: a report of 18 cases.

Kowalewski RJ, MacAdams CL, Eagle CJ, Archer DP, Bharadwaj B.

Can J Anaesth. 1994 Dec;41(12):1189-95.

PMID:
7867115
17.

A patient presenting for pharyngeal biopsy.

Elwood T, Eagle CJ.

Can J Anaesth. 1994 Sep;41(9):861-4.

PMID:
7955005
18.

The cost of an established quality assurance programme: is it worth it?

Eagle CJ, Davies JM, Pagenkopf D.

Can J Anaesth. 1994 Sep;41(9):813-7.

PMID:
7954999
19.

Simple narcotic kits for controlled-substance dispensing and accountability.

Maltby JR, Levy DA, Eagle CJ.

Can J Anaesth. 1994 Apr;41(4):301-5.

PMID:
8004735
20.

The cost of anaesthesia.

Eagle CJ, Kryski S.

Can J Anaesth. 1994 Mar;41(3):265-6. No abstract available.

PMID:
8187266
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk